The Department of Health and Human Services, through the National Institutes of Health (NIH), invites applications for the Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21), aimed at advancing bioengineering solutions applicable to cancer and other biomedical challenges. This funding opportunity, reissuing the PAR-22-090 notice, supports projects that demonstrate feasibility and potential utility of novel capabilities to improve biomedical research, clinical care delivery, and accessibility. Eligible applicants include various higher education institutions, nonprofits, for-profit organizations, and foreign entities, with a funding cap of $275,000 over two years. The initiative specifically discourages clinical trial proposals. The application process is electronic, requiring adherence to strict submission guidelines via Grants.gov. Key review criteria focus on the importance and innovation of proposed research, rigor and feasibility of the approach, and the expertise of the research team. This opportunity encourages multidisciplinary collaborations between bioengineers and biomedical researchers, fostering innovative solutions and technologies to address complex health issues. The overarching goal is to contribute significantly to cancer risk identification, prevention, and the overall advancement of health research.